Charles University Faculty of Pharmacy in Hradec Králové Department of Pharmacology & Toxicology Student: Veronika Halodová Supervisor: doc. PharmDr. Lukáš Červený, Ph.D. Title of diploma thesis: In vitro and ex vivo study of drug-drug interactions of antivirals on intestinal membrane transporters Tenofovir (TFV) is the first-line agent in the treatment of hepatitis B virus (HBV) infection for patients aged over 12 years and one of the first-line choices for the combination antiretroviral therapy (cART) of infections caused by human immunodeficiency virus (HIV). Two commercially available prodrugs have been developed for oral administration of TFV, tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide fumarate (TAF). These prodrugs increase TFV membrane permeability and oral bioavailability. One of the factors that can affect the bioavailability of orally administrated drugs is active transport mediated by efflux transporters, mainly by P-glycoprotein (ABCB1, P-gp) and Breast cancer resistance protein (ABCG2, BCRP). It has been already proved that TDF and TAF are substrates of both of these transporters. The goal of this diploma thesis was to use in vitro and ex vivo models of intestinal barrier to assess the impact of the efflux transporters on TDF and TAF transport in the intestine and on their...

Le pouvoir pathogène des microorganismes repose sur leur capacité à manipuler des processus cellulaires de l'hôte à l'aide de protéines sécrétées dans le tissu végétal : les effecteurs. En plus de leur rôle primordial dans le pouvoir pathogène, les effecteurs sont centraux pour la résistance des plantes. La reconnaissance de certains d'entre eux par des récepteurs du système immunitaire végétal, nommées protéines de résistance (R), déclenche la résistance de la plante. Cette thèse a permis la caractérisation moléculaire d'AVR-CO39, un effecteur du champignon pathogène du riz Magnaporthe oryzae. Nous montrons qu'AVR-CO39 est transloqué dans le cytoplasme des cellules infectées par un mécanisme indépendant de facteurs fongiques et est reconnu dans ce même compartiment par le produit du locus R nommé Pi-CO39. La surexpression d'AVR-CO39 dans des plantes transgéniques révèle que cet effecteur influence des processus développementaux et physiologiques du riz. Un crible double hybride dans la levure a permis d'identifier 9 protéines du riz potentiellement ciblées par AVR-CO39. Une d'elles, nommée RGA5, confère la résistance Pi-CO39 avec une seconde protéine R du riz appelée RGA4. Nos résultats indiquent que RGA4 induit l'activation de la défense tandis que RGA5 agit comme récepteur de protéines Avr. En effet, RGA5 interagit physiquement avec AVR-CO39 et AVR-Pia, un autre effecteur de M. oryzae, via un domaine C-terminal homologue à des protéines de liaison au cuivre. Cette thèse a donc permis l'identification d'un nouveau domaine de reconnaissance de protéines Avr et le développement d'un modèle mécanistique pour le fonctionnement de paires de protéines R chez les plantes. / Pathogenic microorganisms secrete numerous proteins during infection into the plant tissue to manipulate host cellular processes. These proteins are called effectors and are central to pathogenicity. Certain effectors are recognized by receptors of the plant immune system called resistance (R) proteins and this recognition triggers plant resistance. The objective of the thesis was the molecular characterization of AVR-CO39, an effector of the rice blast fungus Magnaporthe oryzae. Localization studies indicate that AVR-CO39 is translocated into the cytoplasm of infected rice-cells by a mechanism independent of fungal factors and that it is recognized within this compartment by the product of the corresponding R locus Pi-CO39. Overexpression of AVR-CO39 in transgenic rice plants suggests that the effector influences plant physiology and development. Yeast two-hybrid screening identified 9 rice proteins potentially targeted by AVR-CO39. One of them, called RGA5, interacts with a second R protein, RGA4, to confer Pi-CO39 resistance. Our results suggest that RGA4 activates plant defense while RGA5 represses RGA4 function in the absence of effectors proteins and acts as an Avr receptor protein. Indeed, RGA5 physically interacts with AVR-CO39 and another M. oryzae effector named AVR-Pia through a previously undescribed C-terminal domain displaying homology to copper-binding proteins. Therefore, this work identified a new Avr recognition domain in R proteins and generated a new mechanistic model for the action of R protein pairs in plant resistance.

Mother's milk provides multiple benefits to the offspring. However, xenobiotics transferred into breast milk may pose a risk to the nursing infant. The breast cancer resistance protein (BCRP) actively transports xenobiotics into breast milk. BCRP also transports nutrients, like riboflavin, and together with recently identified riboflavin transporters (RFT), may provide a mechanism for riboflavin secretion into breast milk. Expression of RFT in the mammary gland remained unknown. Our objective was to characterize Bcrp and Rft mRNA expression in the mammary gland of FVB/N mice, and investigate a strategy to decrease excretion of BCRP-transported xenobiotics into the milk using riboflavin intervention. Rft and Bcrp mRNA were upregulated in the mammary gland of lactating mice. An intravenous riboflavin administration significantly reduced the levels of BCRP-transported cimetidine in milk. This study demonstrates the use of riboflavin to exploit the function of mammary BCRP in order to reduce xenobiotic secretion into breast milk.

Mother's milk provides multiple benefits to the offspring. However, xenobiotics transferred into breast milk may pose a risk to the nursing infant. The breast cancer resistance protein (BCRP) actively transports xenobiotics into breast milk. BCRP also transports nutrients, like riboflavin, and together with recently identified riboflavin transporters (RFT), may provide a mechanism for riboflavin secretion into breast milk. Expression of RFT in the mammary gland remained unknown. Our objective was to characterize Bcrp and Rft mRNA expression in the mammary gland of FVB/N mice, and investigate a strategy to decrease excretion of BCRP-transported xenobiotics into the milk using riboflavin intervention. Rft and Bcrp mRNA were upregulated in the mammary gland of lactating mice. An intravenous riboflavin administration significantly reduced the levels of BCRP-transported cimetidine in milk. This study demonstrates the use of riboflavin to exploit the function of mammary BCRP in order to reduce xenobiotic secretion into breast milk.

All living organisms utilize thousands of molecular building blocks to perform mechanical tasks. These building blocks are mostly proteins, and their mechanical properties define the way they can be utilized by the cell. The spectrum ranges from rope like structures that give hold and stability to our bodies to microscopic engines helping us to perform or sense mechanical work. An increasing number of biological processes are revealed to be driven by force and well-directed distribution of strain is the very base of many of these mechanisms. We need to be able to observe the distribution of strain within bio-molecules if we want to gain detailed insight into the function of these highly complex nano-machines. Only by theoretical understanding and prediction of mechanical processes on the molecular level will we be able to rationally tailor proteins to mimic specific biological functions. This thesis aims at understanding the molecular mechanics of a wide range of biological molecules, such as the muscle protein titin or silk fibers. We introduce Force Distribution Analysis (FDA), a new approach to directly study the forces driving molecular processes, instead of indirectly observing them by means of coordinate changes.

Multidrug resistance protein 2 (MRP2) is the second member the C subfamily in the superfamily of adenosine triphosphate (ATP)-binding cassette (ABC) efflux transporters. MRP2 is a critical player for generation of bile acidindependent bile flow and biliary excretion of glutathione, glucuronate and sulfate conjugates of endo- and xenobiotics. Dysfunctional expression of MRP2 is associated with Dubin-Johnson Syndrome. Pathological and physiological states or xenobiotics change the MRP2 expression level. Under some conditions, expression of the human MRP2 and rat Mrp2 proteins are regulated at the translation level. There are several transcription initiation sites in MRP2/Mrp2 gene. The 5’ untranslated regions (5’UTRs) of MRP2/Mrp2 contains multiple translation start codons. The focus of this study, therefore, was investigation of the translational regulatory mechanisms mediated by the upstream open reading frames (uORF) of MRP2/Mrp2. Using in vitro translation assays and transient cotransfection assays in HepG2 cells, we showed that the rat uORF1 starting at position -109 (relative to the ATG of Mrp2) and the human uORF2 starting at position -105 (relative to the ATG of MRP2) are two major cis-acting inhibitors of translation among the rat and human multiple uORFs, respectively. Translational regulation mediated by the uORFs in the rat Mrp2 mRNA is a combined effect of the leaky scanning model and the reinitiation model, and also results from interaction of the multiple uORFs. In addition, by Ribonuclease Protection Assays (RPA), we detected multiple transcription initiation sites of MRP2/Mrp2 gene in tissues. We also found that the relative abundance of the rat Mrp2 mRNA isoforms with different 5’UTRs differed in the rat liver, kidney, jejunum, ileum, placenta, and lung. This is the first study on the translational regulatory mechanisms of the MRP2/Mrp2 gene.

<p>The appearance of adverse drug reactions is a common reason for hospitalization in Western countries. Research on underlying biological mechanisms for interindividual variability in drug response aims to better identify patients with exceptional genetic traits, disease conditions or risk of drug-drug interactions and thereby help to prevent adverse drug reactions. </p><p>Active transport mechanisms are involved in the absorption and disposition of several therapeutic agents. The main objective of this thesis was to investigate factors potentially affecting transport proteins and thus contributing to variability in drug absorption and disposition. Studies of physiological, genetic, environmental, and pathological factors were included. The main focus was the two ATP-binding cassette (ABC) transporters: P-glycoprotein 170 (Pgp) and Breast Cancer Resistance Protein (BCRP). </p><p>Quantification of transport protein mRNAs along the human intestine indicated that eight of the nine investigated drug transporters were expressed in a region-dependent manner. Effects of drug-drug interactions may therefore vary depending on the site of absorption. The genetic aspect was illustrated by identification of sequence variation in the gene encoding BCRP, the most highly expressed ABC transporter along the human intestine. Drug-drug interactions are important environmental causes of interindividual variability. An evaluation of the effects of Pgp-mediated drug-drug interactions showed that patients receiving Pgp inhibitors had elevated serum concentrations of the Pgp substrate digoxin and that digoxin concentrations were positively correlated with the number of co-administered Pgp inhibitors. The final topic in this thesis was that of drug-disease interactions. BCRP and Pgp were down-regulated during active inflammation in patients with ulcerative colitis. This may contribute to altered concentrations of drug in the intestinal mucosa during periods of inflammation and possibly to changes in drug absorption.</p><p>To summarize, results of this thesis emphasize the complex background to the interindividual variability of drug transport proteins, where physiological, genetic, environmental and pathological factors all can contribute.</p>

The appearance of adverse drug reactions is a common reason for hospitalization in Western countries. Research on underlying biological mechanisms for interindividual variability in drug response aims to better identify patients with exceptional genetic traits, disease conditions or risk of drug-drug interactions and thereby help to prevent adverse drug reactions. Active transport mechanisms are involved in the absorption and disposition of several therapeutic agents. The main objective of this thesis was to investigate factors potentially affecting transport proteins and thus contributing to variability in drug absorption and disposition. Studies of physiological, genetic, environmental, and pathological factors were included. The main focus was the two ATP-binding cassette (ABC) transporters: P-glycoprotein 170 (Pgp) and Breast Cancer Resistance Protein (BCRP). Quantification of transport protein mRNAs along the human intestine indicated that eight of the nine investigated drug transporters were expressed in a region-dependent manner. Effects of drug-drug interactions may therefore vary depending on the site of absorption. The genetic aspect was illustrated by identification of sequence variation in the gene encoding BCRP, the most highly expressed ABC transporter along the human intestine. Drug-drug interactions are important environmental causes of interindividual variability. An evaluation of the effects of Pgp-mediated drug-drug interactions showed that patients receiving Pgp inhibitors had elevated serum concentrations of the Pgp substrate digoxin and that digoxin concentrations were positively correlated with the number of co-administered Pgp inhibitors. The final topic in this thesis was that of drug-disease interactions. BCRP and Pgp were down-regulated during active inflammation in patients with ulcerative colitis. This may contribute to altered concentrations of drug in the intestinal mucosa during periods of inflammation and possibly to changes in drug absorption. To summarize, results of this thesis emphasize the complex background to the interindividual variability of drug transport proteins, where physiological, genetic, environmental and pathological factors all can contribute.

Made available in DSpace on 2014-06-11T19:31:11Z (GMT). No. of bitstreams: 0 Previous issue date: 2008-12-18Bitstream added on 2014-06-13T19:20:17Z : No. of bitstreams: 1 gerardi_dg_dr_jabo.pdf: 906206 bytes, checksum: 29e6a477f11cbcccee68cc2a21495f1a (MD5) / Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) / Tendo em vista a expressão da proteína associada à resistência a múltiplas drogas (MRP1), da enzima glutationa-S-transferase pi (GSTpi) e da proteína p53 com o desenvolvimento da resistência a múltiplas drogas (RMD) nas células neoplásicas, objetivou-se neste estudo avaliar a expressão desses três marcadores, pela imunoistoquímica, em 68 espécimes de neoplasias caninas, incluindo tumores venéreos transmissíveis (TVTC), mastocitomas, carcinomas mamários e de glândula hepatóides e linfomas. Os espécimes foram subdivididos em: TVT, Tumor venéreo transmissível (n=9); TVTR, TVTs resistentes à quimioterapia (n=5); MASTI, mastocitomas cutâneos grau I (n=8); MASTIII, mastocitomas cutâneos grau III (n=8); CARM, carcinomas mamários (n=14); CARH, carcinomas de glândulas hepatóides (n=8); LINFB, linfomas de células B (n=9); LINFT, linfomas de células T (n=7). Resultados mostraram que as expressões da MRP1, GSTpi e p53 foram observadas em 38 (55%), 43 (62,3%) e 50 (72,4%) espécimes, respectivamente. Em 27 (39,1%) espécimes houve coexpressão dos três marcadores. A expressão da MRP1, GSTpi e p53 isoladas ou associadas pôde ser observada em todos os grupos experimentais, exceto o grupo TVTC que não expressou a MRP1. A localização da marcação nas células tumorais foi citoplasmática para MRP1 e nuclear e/ou citoplasmática para a GSTpi e p53. Não foi observada diferença na expressão dos marcadores de resistência a quimioterapia em relação à resistência a quimioterapia (TVT e TVTR), gradação histológica (MASTI e III) e imunofenótipo (LINFB e T). Há relação direta entre o aumento da expressão da MRP1 e da GSTpi nos linfomas T. / Multidrug resistance in tumors involves the expression of multidrug resistance protein-1 MRP1, enzyme glutathione-S-transferase pi (GSTpi), and p53 protein. Therefore, this study aimed at evaluating the expression of these three markers, by immunohistochemistry, in neoplasic cells. Sixty-eight canine tumor samples, including transmissible venereal tumor (TVTC), cutaneous mast cell tumor, mammary carcinoma, hepatoid gland carcinoma, and lymphoma were studied. Samples were assigned into one of the following subgroups: TVT, transmissible venereal tumor (n=9); TVTR, chemoresistant TVT (n=5), MASTI, grade-I cutaneous mast cell tumor (n=8); MASTIII, grade-III cutaneous mast cell tumor (n=8); CARM, mammary carcinoma (n=14); CARH, hepatoid gland carcinoma (n=8); LINFB, B-cell lymphoma (n=9); LINFT, T-cell lymphoma (n=7). We observed that 38 (55%), 43 (62.3%), and 50 (72.4%) samples expressed MRP1, GSTpi, and p53, respectively. Co-expression of the three markers was present in 27 (39.1%) samples. Expression of MRP1, GSTpi, and p53 alone or associated could be observed in all experimental groups, except for TVT group which did not express MRP1. Staining in the tumor cells was cytoplasmatic to MRP1, and both nuclear and cytoplasmatic to GSTpi and p53. No significant difference in the expression of the markers could be observed with relation to chemoresistance (TVT and TVTR), histological grade (MASTI and MASTIII) and immunophenotype (LINFB and LINFT). A direct relation was present between the raise of the expression of MRP1 and GSTpi in T cells lymphoma.

Orientadora: Mirela Tinucci Costa / Banca: Renée Laufer Amorim / Banca: Carlos Roberto Daleck / Banca: Felipe Augusto Ruiz Sueiro / Banca: Noeme Sousa Rocha / Resumo: Tendo em vista a expressão da proteína associada à resistência a múltiplas drogas (MRP1), da enzima glutationa-S-transferase pi (GSTpi) e da proteína p53 com o desenvolvimento da resistência a múltiplas drogas (RMD) nas células neoplásicas, objetivou-se neste estudo avaliar a expressão desses três marcadores, pela imunoistoquímica, em 68 espécimes de neoplasias caninas, incluindo tumores venéreos transmissíveis (TVTC), mastocitomas, carcinomas mamários e de glândula hepatóides e linfomas. Os espécimes foram subdivididos em: TVT, Tumor venéreo transmissível (n=9); TVTR, TVTs resistentes à quimioterapia (n=5); MASTI, mastocitomas cutâneos grau I (n=8); MASTIII, mastocitomas cutâneos grau III (n=8); CARM, carcinomas mamários (n=14); CARH, carcinomas de glândulas hepatóides (n=8); LINFB, linfomas de células B (n=9); LINFT, linfomas de células T (n=7). Resultados mostraram que as expressões da MRP1, GSTpi e p53 foram observadas em 38 (55%), 43 (62,3%) e 50 (72,4%) espécimes, respectivamente. Em 27 (39,1%) espécimes houve coexpressão dos três marcadores. A expressão da MRP1, GSTpi e p53 isoladas ou associadas pôde ser observada em todos os grupos experimentais, exceto o grupo TVTC que não expressou a MRP1. A localização da marcação nas células tumorais foi citoplasmática para MRP1 e nuclear e/ou citoplasmática para a GSTpi e p53. Não foi observada diferença na expressão dos marcadores de resistência a quimioterapia em relação à resistência a quimioterapia (TVT e TVTR), gradação histológica (MASTI e III) e imunofenótipo (LINFB e T). Há relação direta entre o aumento da expressão da MRP1 e da GSTpi nos linfomas T. / Abstract: Multidrug resistance in tumors involves the expression of multidrug resistance protein-1 MRP1, enzyme glutathione-S-transferase pi (GSTpi), and p53 protein. Therefore, this study aimed at evaluating the expression of these three markers, by immunohistochemistry, in neoplasic cells. Sixty-eight canine tumor samples, including transmissible venereal tumor (TVTC), cutaneous mast cell tumor, mammary carcinoma, hepatoid gland carcinoma, and lymphoma were studied. Samples were assigned into one of the following subgroups: TVT, transmissible venereal tumor (n=9); TVTR, chemoresistant TVT (n=5), MASTI, grade-I cutaneous mast cell tumor (n=8); MASTIII, grade-III cutaneous mast cell tumor (n=8); CARM, mammary carcinoma (n=14); CARH, hepatoid gland carcinoma (n=8); LINFB, B-cell lymphoma (n=9); LINFT, T-cell lymphoma (n=7). We observed that 38 (55%), 43 (62.3%), and 50 (72.4%) samples expressed MRP1, GSTpi, and p53, respectively. Co-expression of the three markers was present in 27 (39.1%) samples. Expression of MRP1, GSTpi, and p53 alone or associated could be observed in all experimental groups, except for TVT group which did not express MRP1. Staining in the tumor cells was cytoplasmatic to MRP1, and both nuclear and cytoplasmatic to GSTpi and p53. No significant difference in the expression of the markers could be observed with relation to chemoresistance (TVT and TVTR), histological grade (MASTI and MASTIII) and immunophenotype (LINFB and LINFT). A direct relation was present between the raise of the expression of MRP1 and GSTpi in T cells lymphoma. / Doutor